The impact of hypertension in hemodialysis patients

Current Hypertension Reviews

Volumn 4, Issue 2, 2008, Pages 100-106

  Fagugli, Riccardo Maria ^a   Taglioni, Chiara ^a   Rossi, Davide ^b   Ricciardi, Daniela ^b  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b ASUR ^*  (Italy)

Author keywords

Hemodialysis; Hypertension; Mortality

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; VASODILATOR AGENT; VITAMIN D DERIVATIVE;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL COMPLIANCE; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEALTH SURVEY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART STRESS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MONOTHERAPY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SODIUM RESTRICTION; SURVIVAL; SYMPATHETIC TONE;

EID: 48249108386     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340208784245901     Document Type: Review

References (90)

1. Foley RN, Parfrey PS. Risk factors for cardiac morbidity and mortality in dialysis patients. Curr Opin Nephrol Hypertens 1994; 3: 608-14.
2. Horl MP, Horl WH: Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 2002; 39: 227-244.
3. http://www.usrds.org/2001pdf/h.pdf.
4. http://www.sin-ridt.org/.
5. Locatelli F, Covic A, Chazot C, Leunissen K, Luño J, Yaqoob M. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant Advance Access published on March 5, 2004.
6. Vertes V, Cangiano JL, Berman LB, Gould A. Hypertension in end-stage renal disease. N Engl J Med 1969; 280: 978-998.
7. Stokes GS, Mani NIK, Stewart JH. relevance of salt, water and renin to hypertension in chronic renal failure. Br Med J 1970; 3: 126.
8. M. P. Horl and W.H. Horl. Hemodialysis-associated hypertension. Am J Kidney Dis 2002; 39: 227-244.
9. Agarwal R. Systolic hypertension in hemodialysis patients. Semin Dial. 2003; 16: 208-213.
10. Zoccali C, Mallamaci F, Tripepi G, et al. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients. J Hypertens 1999; 17: 1751-1758.
11. Nishikimi T, Minami J, Tamano K, et al. Left ventricular mass relates to average systolic blood pressare, but not loss of circadian blood pressure in stable hemodialysis patients: an ambulatory 48-hour blood pressure study. Hypertens Res 2001; 24: 507-514.
12. Conlon PJ, Walshe JJ, Heinle SK, Minda S, Krukoff M, Schwab SJ. Predialysis systolic blood pressure correlates strongly with 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol 1996; 7: 2658-2663.
13. Covic A, Goldsmith DJ, Covic M. Reduced blood pressure diurnal variability as a risk factor for progressive left ventricular dilatation in hemodialysis patients. Am J Kidney Dis. 2000; 35: 617-23.
14. Fagugli RM, Quintaliani G, Pasini P, et al. Blunted nocturnal blood pressure decrease and left ventricular mass in hypertensive hemodialysis patients. Nephron 2002; 91: 79-85.
15. Foley RN, Parfrey PS, Kent GM, et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000; 11: 912-916.
16. Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 2004; 65: 1492-1498.
17. Zager PG, Nikolic J, Brown RH, et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998; 54: 561-569.
18. Mazzucchi N, Carbonell E, Fernandez-Cean J. Importance of blood pressure control in hemodialysis patients survival. Kidney Int 2000; 58: 2147-2154.
19. Kalantar-Zadeh K, Kilpatric RD, McAllister CJ, Greenland S, Kopple JD. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 2005; 45: 811-817.
20. Salem MM. Hypertension in hemodialysis population: any relationship to 2-years survival? Nephrol Dial Transpl 1999; 14: 125-128.
21. Stidley CA, Hunt WC, Tentori F, et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am See Nephrol 2006; 17: 513-520.
22. Li Z, Lacson E, Lowrie EG, et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006; 48: 606-615.
23. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999; 33: 507-517.
24. Foley RN, Herzog CA, Collins AJ. Blood pressure and long term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62: 1784-1790.
25. Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 2002; 61: 717-726.
26. Takeda A, Toda T, Fujii T, Shinohara S, Sasaki S, Matsui N. Discordance of influence on mortality and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2004; 45: 112-118.
27. Tripepi G, Fagugli RM, Dattolo P, et al. Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in non diabetic, cardiovascular events-free patients. Kidney Int 2005; 68: 1294-1302.
28. Amar J, Vernier I, Rossignol E, et al. Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 2000; 57: 2485-2491.
29. Foley RN, Parfrey PS, Harnett JD, et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996; 49: 1379-1385.
30. Chen CH, Lin YP, Yu WC, Yang WC, Ding YA: Volume status and blood pressure during long term hemodialysis, role of ventricular stiffness. Hypertens 2003; 42: 257-262.
31. Fagugli RM, Pasini P, Quintaliani G, et al. Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients. Nephrol Dial Transplant. 2003; 18: 2332-8.
32. Inrig JK, Oddone EZ, Hasselblad V, et al. Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients. Kidney Int 2007; 71: 454-461.
33. Cannella G, Paoletti E, Ravera G, et al. Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients. Kidney Int 2000; 58: 260-268.
34. Peixoto AJ, Santos SF, Mendes RB, et al. Reproducibility of ambulatory blood pressure monitoring in hemodialysis patients. Am J Kidney Dis 2000; 36: 983-990, 2000.
35. Rahman M, Griffin V, Kumar A, et al. A comparison of standardized versus "usual" blood pressure measurements in hemodialysis patients. Am J Kidney Dis 2002; 39: 1226-1230.
36. Amar J, Vernier I, Rossignol E, et al. Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 2000; 57: 2485-2491.
37. Nishikimi T, Minami J, Tamano K, et al. Left ventricular mass relates to average systolic blood pressure, but not loss of circadian blood pressure in stable hemodialysis patients: an ambulatory 48-hour blood pressure study. Hypertens Res 2001; 24: 507-514.
38. Conlon PJ, Walshe JJ, Heinle SK, Minda S, Krukoff M, Schwab SJ. Predialysis systolic blood pressure correlates strongly with 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol 1996; 7: 2658-2663.
39. Agarwal R, Brim NJ, Mahenthiran J, Andersen MJ, Saba C. Out-of-hemodialysis-unit blood pressure is a superior determinant of left ventricular hypertrophy. Hypertension 2006; 47: 62-68.
40. Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2004; 12: 2768-74.
41. Mendes RB, Santos F, Dorigo D, et al. The use of peridialysis blood pressure and intradialytic blood pressure changes in the prediction of interdialytic blood pressure in hemodialysis patients. Blood Press Monit 2003; 8: 243-248.
42. Agarwal R, Andersen MJ, Bishu. K, Saba C. Home blood pressure monitoring improves the diagnosis of hypertension in home hemodialysis. Kidney Int 2006; 69: 900-906.
43. Scribner BH. A personalised history of hemodialysis. Am J Kidney Dis 1990; 16: 511-519.
44. Ritz E, Koomans HA. New insight into mechanism of blood pressure regulation in patients with uremia. Nephrol Dial Transplant 1996; 11: 52-59.
45. Mailloux LU, Haley WE. Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 1998; 32: 705-719.
46. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney International 1992; 41: 1286-1291.
47. Fagugli RM, Reboldi G, Quintaliani G, et al. Short daily haemodialysis: blood pressure control and left ventricular mass reduction in hypertensive haemodialysis patients. Am J Kid Dis 2001; 38: 371-376.
48. Luik AJ, van der Sande FM, Weideman P, Cheriex E, Kooman JP, Leunissen KM. The influence of increasing dialysis treatment time and reducing dry weight on blood pressure control in hemodialysis patients: a prospective study. Am J Nephrol 2001; 21: 471-478.
49. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002; 61: 2235-9.
50. Ozkahya M, Toz H, Unsal A, et al. Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor. Am J Kidney Dis 1999; 34: 218-221.
51. Guyton AC. Renal function curve: a key to understanding the pathogenesis ofitypertension? Hypertension 1987; 10: 1-6.
52. Charra B. Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int 2007; 11: 21-31.
53. Chen CH, Lin YP, Yu WC, Yang WC, Ding YA. Volume status and BloodPressure During Long-Term Hemodialysis. Role of ventricular stiffening. Hypertension 2003; 42: 257-262.
54. Leypoldt JK, Cheung AK, Delmer JA, et al. Relationship between volume status and blood pressure during hemodialysis. Kidney Int 2002; 61: 266-275.
55. Neuman J, Ligtenberg G, Klein H, Koomans HA, Blankestijn PJ. Sympatethic hyperactivity in chornic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65: 1568-1576.
56. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995; 26: 861-865.
57. Ye S, Ozgur M, Campese VM. Renal afferent impulses, the posterior hypothalamus and hypertension in rats with chronic renal failure. Kidney Int 1997; 51: 722-727.
58. Campese VM. Neurogenic factors and hypertension in renal disease. Kidney hit 2000; 57: S2-6.
59. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918.
60. Zoccali C, Mallamaci F, Tripepi G. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol. 2002 Mar; 13: 729-33
61. Liu M, Takahashi H, Morita Y, et al. Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in hemodialysis patients. Nephrol Dial Transplant 2003; 18: 563-569
62. Shichiri M, Hirata Y, Ando K, et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990; 15: 493-496.
63. Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uremia. Lancet 1989; 1 (8645): 991-992.
64. Suzuki N, Matsumoto H, Miyauchi T, et al. Endothelin-3 concentrations in human plasma: the increased concentrations in patients undergoing haemodialysis. Biochem Biophys Res Commun 1990; 169: 809-815.
65. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339 (8793): 572-575.
66. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001; 358: 2113-7.
67. London GM, Guerin AP, Marchais SJ. Pressure-overload cardiomiopathy in end-stage renal disease. Curr Opin Nephrol Hypertens 1999; 8: 179-186.
68. London GM, Guerin AP, Marchais SJ. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996; 50: 600-608.
69. Goodman WG, Goldin J, Kuizon BD, et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
70. Raine AE, Bedford L, Simpson AW, et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993; 43: 700-705.
71. Goldsmith DJ, Covic AA, Venning MC, Ackrill P. Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: further evidence implicating calcium homeostasis in blood pressure regulation. Am J Kidney Dis 1996; 27: 819-825.
72. Zucchelli P, Santoro A, Zuccalà A. Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 1988; 8: 103-167.
73. Shimada N, Saka S, Sekizuka K, et al. Increased endothelin: nitric oxide ratio is associated with crythropoietin-induced hypertension in hemodialysis patients. Ren Fail 2003; 25: 569-578.
74. Locatelli F, Covic A, Chazot C, Leunissen K, Luno J, Yaqoob M. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant 2004; 19: 1058-68
75. Griffith TF, Chua BSY, Allen AS, Klassen PS, Reddan DN, Szczech LA. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2003; 42: 1260-1269.
76. Iseki K, Nakai S, Shinzato T, et al. Prevalence and Determinants of Hypertension in Chronic Hemodialysis Patients in Japan. Ther Apher Dial 2007; 11: 183-188.
77. Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD. Reninangiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 2002; 112: 110-114.
78. Castellino P, Bia MJ, DeFronzo RA. Adrenergic modulation of potassium metabolism in uremia. Kidney Int 1990; 37: 793-798.
79. Ertürk S, Ates K, Duman N, Karatan O, Erbay B, Ertug E. Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: possible implications of angiotensin-converting enzyme inhibitors. Nephrol Dial Transplant 1996; 11: 396-397.
80. Efrati S, Zaidenstein R, Dishi V, et al. ACE inhibitors and survival ofhemodialysis patients. Am J Kidney Dis 2002; 40: 1023-1029.
81. Zannad F, Messer M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for furure studies. Kidney Int 2006; 70: 1318-1324.
82. Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256-261.
83. Kanno Y, Kaneko K, Kaneko M, et al. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 2004; 43: 380.386.
84. Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on the regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial 2004; 8: 320-327.
85. Fagugh RM, Pasini P, Pasticci F, Ciao G, Cicconi B, Buoncristiani U. Effects of short daily hemodialysis and extended standard hemodialysis on blood pressure and cardiac hypertrophy: a comparative study. J Nephrol. 2006; 19: 77-83.
86. Rahman N, Dixit A, Donley V, et al. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis 1999; 33: 498-506.
87. Inrig JK, Patel UD, Gillespie BS, et al. Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients. Am J Kidney Dis 2007; 50: 108-118.
88. Anderson JE, Boivin MR, Hatchett L. Effect of exercise training on interdialytic ambulatory and treatment-related blood pressure in hemodialysis patients. Ren Fail 2004; 26: 539-544.
89. Schroeder M, Riedel E, Beck W, Deppish RM, Pommer W. Increased reduction of dimethylarginines and lowered blood pressure by the use of biocompatible membranes. Kiney Int Suppl 2001; 78: S19-24.
90. Maduell F, del Pozo C, Garcia H, et al. Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Tranplant 1999; 14: 1202-1207.